- Conditions
- Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Los Angeles, California + 35 more
Condition Directory
Melanoma clinical trials
Directory of U.S. ClinicalTrials.gov public records for Melanoma. Browse Melanoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 29, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2277
Shown on this page
12
Current sort
Recently updated
Condition scope
Melanoma
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Melanoma studies are organized in the registry
Melanoma listings distinguish cutaneous from uveal (eye) melanoma, and the treatment setting — adjuvant after surgery versus advanced/metastatic disease — is usually stated in the title. Both distinctions are worth including in a query because the resulting study populations rarely overlap.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 565–576 of 2,277 matching trials for Melanoma.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Interventions
- BNT111, Cemiplimab
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
- Interventions
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Biological
- Lead sponsor
- AgonOx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cutaneous Melanoma, Synovial Sarcoma
- Interventions
- IMA203, mRNA-4203
- Biological
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Melanoma, Gastrointestinal Neoplasms, Genitourinary Cancer, Thoracic Cancer, Sarcoma
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
- Interventions
- [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
- Drug · Biological
- Lead sponsor
- Fusion Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 7
- States / cities
- Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
- Conditions
- Melanoma
- Interventions
- screening questionnaire
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cutaneous Melanoma
- Interventions
- Nivolumab (480 mg infusion), NeoVax plus Montanide, Ipilimumab
- Drug · Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Melanoma, Melanoma Brain Metastasis
- Interventions
- NovoTTF-200A, Pembrolizumab
- Device · Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
- Interventions
- PET scan with 124I-cRGDY-PEG-dots
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- Poly-ICLC, Peptides
- Biological
- Lead sponsor
- Patrick Ott, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Solid Tumor, Unresectable or Metastatic Melanoma
- Interventions
- CX-072, Ipilimumab
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
About this Melanoma clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Melanoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Melanoma.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Melanoma.